Clinical Trials Logo

Filter by:
  • Enrolling by invitation  
  • Page [1] ·  Next »
NCT ID: NCT06448065 Enrolling by invitation - Cerebral Palsy Clinical Trials

Gait Classification in Children With Cerebral Palsy, a Reliability Study

GCP
Start date: April 20, 2024
Phase:
Study type: Observational

The goal of this observational study is to assess whether gait classification patterns can be reliably obtained from video recordings in comparison with three-dimensional kinematic data. The main questions it aims to answer are: Are gait classifications from video recordings reliable between raters? Are gait classifications from video recordings valid in comparison with three-dimensional kinematic data? Gait analysis data from participants who visited the gait lab in the Karolinska Hospital will be used for this purpose.

NCT ID: NCT06431659 Enrolling by invitation - Death Clinical Trials

Swedish Palliative Care Guide (S-PCG) at Residential Facilities

Start date: May 20, 2024
Phase:
Study type: Observational

Palliative care aims to improve the quality of life for patients and families who are affected life-threatening, incurable disease. The care should be person-centred, but it is not entirely clear how this is best achieved. The Institute for Palliative Care, Lund, has developed the Swedish Palliative Care Guide (S-PCG) which support for a person-centred approach throughout the palliative care process. The aim of this study is to implement the Swedish Palliative Care Guide (S-PCG) part 2 at Residential Facilities and evaluate functionality, effect and patient benefit in clinical use.

NCT ID: NCT06421961 Enrolling by invitation - Clinical trials for Chronic Limb-Threatening Ischemia

Agreement Study on AI-assisted Smartphone-based Monitoring Tool for Difficult-to-heal Ischemic Leg Ulcers

Start date: August 15, 2024
Phase:
Study type: Observational

The purpose of the project is to investigate the agreement with Bland-Altman plots between an AI-supported automatic digital measurement method of wound area and depth and existing manual measurement methods in patients with arterial ulcers on the lower leg. The expectation is that the digital measurement tool can provide healthcare providers with better opportunities to objectively monitor and detect changes in the wound healing process in patients with peripheral arterial disease.

NCT ID: NCT06401720 Enrolling by invitation - Clinical trials for SARS CoV 2 Infection

Age Related Differences in Respiratory Immune Responses in Influenza Virus Infection

NPA-DC
Start date: January 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to understand immune responses to viral airway infection in adults, including the elderly. The main question(s) to answer is/are: Why do some individuals acquire only asymptomatic or mild Influenza A virus (IAV) infection while others become severely ill and even succumb to the same disease? Participants will be asked to donate samples when seeking health care for influenza-like symptoms or if hospitalized for IAV or SARS-CoV-2. Samples asked for are: - Blood sample by venepuncture - Blood sample by capillary sampling - Nasopharyngeal aspirate - Nasopharyngeal swab - Endotracheal tube aspirate - Nasal swab - Nasal curette - Breath Explor (sampling of expired air) Researchers will compare obtained results with the same type of samples from healthy controls.

NCT ID: NCT06330116 Enrolling by invitation - Clinical trials for Sleep Apnea, Obstructive

Different Forms of OMT as Methods for Reducing Snoring and Mild to Moderate Sleep Apnea

SNORT
Start date: March 29, 2024
Phase: N/A
Study type: Interventional

Objective the present project aims to assess the impact of 1) oral screen training, group training, and the use of neuromuscular electrical training (NMES) as orofacial myofunctional therapy (OMT) methods for reducing the apnea-hypopnea index (AHI) among adults with mild to moderate sleep apnea and 2) if these different training methods can reduce snoring and affect the level of sleepiness and quality of life. Study design The study will use a prospective randomized open-blinded endpoint (PROBE) design with baseline measurements, intervention phase, and follow-up measurements. Methods 141 consecutive adult subjects, 71 men and 70 women referred to hospital, due to symptoms of snoring and mild to moderate sleep apnea will be randomized, included, and examined at three different sites, Umeå(Sweden), Lund(Sweden) and Köge(Denmark) One hundred-five of them, 35 in each treatment group, will receive one of the three different forms of training and the final 36 persons serving as controls, age/AHI matched (18 in Köge resp Umeå). Participants in Umeå will be randomized to either training with IQoro or serving as controls. Participants in Köge will be randomized to either training with Exciteosa, group training, or controls. The primary outcome is a change in AHI before and after three months of training with the different methods according to overnight ambulatory sleep apnea recordings. The secondary outcomes are change in snoring frequency, sound level dB (A) according to a questionnaire, the Basic Nordic Sleep Questionnaire (BNSQ), daytime sleepiness using the Epworth Sleepiness Scale (ESS), change in quality of life using the short form -36 (SF-36) and muscle strength in tongue before and after treatment.

NCT ID: NCT06285630 Enrolling by invitation - Healthy Clinical Trials

The Development and Health of the Intestinal Flora During the First Year of Life

PREVENT
Start date: February 26, 2024
Phase:
Study type: Observational

In this research study (PREVENT 1), Alba Health, in collaboration with academic institutions (Uppsala University, COPSAC and University of Antwerp) is investigating the association between the developing gut microbiota (collection of microbes present in the human gut) in the first year of life and lifestyle, wellbeing and health in a Swedish population. The study is the first of its kind in a Swedish population to collect and associate microbiome composition to an extensive family history and health questionnaire, stool colour and crying type, building on learnings from previous studies performed in other countries, such as the HELMI and COPSAC studies (HELMI - Finnish Health and Early Life Microbiota cohort from the University of Helsinki in Finland; COPSAC - Copenhagen Prospective Studies on Asthma in Childhood in Denmark). The PREVENT 1 study is an observational research study led by Alba Health involving 300 families in Sweden with children between 0 and 12 months of age at the time of the study's start. After providing informed consent, the participating families will be asked to provide three stool samples from their child (the sample collection is not invasive and does not cause discomfort) and will be asked to answer questionnaires on lifestyle, well-being and family health. The participating families will not be asked to change their lifestyle beyond sample and data collection. From the collected stool samples, we will extract microbial DNA and subject this to deep metagenomic sequence analysis. The study will only analyze microbial DNA, any human related material will be discarded. The stool samples will be destroyed within one month of sequencing (maximum 3 months from collection). The data will be stored according to GDPR and Swedish law, with informed consent in Sweden and with appropriate security measures. All research will be carried out in Sweden.

NCT ID: NCT06283576 Enrolling by invitation - Pancreatic Cancer Clinical Trials

Pancreatic Cancer Initial Detection Via Liquid Biopsy

PANCAID
Start date: May 1, 2024
Phase:
Study type: Observational

The overall rationale of PANCAID is to provide a diagnostic blood test for early diagnosis of pancreatic cancer. With a set of different liquid biopsy methods, it is the aim to measure these markers in well-defined patient cohorts. For the entire series of these studies, the following groups are planned: 1) Histologically proven early-stage pancreatic cancer (e.g. T1a/b and T2 carcinomas [N0M0]); 2) Intraductal papillary mucinous neoplasia (IPMN) that were operated with verification of the benign, premalignant or malignant histology; 3) ordinary branched-duct IPMN; 4) individuals at risk (IAR) with and without IPMN, with and without known hereditary cancer gene (e.g. BRCA2); 5) a high risk group of patients with chronic pancreatitis, aged 55-65, who are heavy smokers (≥40 PY), with newly onset diabetes mellitus (NODM).

NCT ID: NCT06273501 Enrolling by invitation - Vulvar Cancer Clinical Trials

MRI and Magnetometer-guided Sentinel Lymph Node Detection in Vulvar Cancer

POSVUC
Start date: March 24, 2022
Phase: N/A
Study type: Interventional

The aim of the feasibility study is to evaluate whether SPIO-MRI and a magnetometer could be a potential substitute to the routine dual technique in pre-and intraoperative SLN localization. Secondary, to explore if SPIO-MRI could predict lymph node status in comparison to histopathological analysis.

NCT ID: NCT06261411 Enrolling by invitation - Thoracic Surgery Clinical Trials

Lung Ultrasound as Alternative to Radiation in Thoracic Surgery

LUS-ART
Start date: February 12, 2024
Phase: N/A
Study type: Interventional

This projects aim is to study the effects of substitute conventional chest x-ray with lung ultrasound for patients undergoing thoracic surgery. Participants in the study will be randomized to either ultrasound or routine chest x-ray as the primary method of diagnosis after having received surgery to their lungs.

NCT ID: NCT06212050 Enrolling by invitation - Aortic Stenosis Clinical Trials

Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis

Neo2BAV
Start date: September 15, 2023
Phase:
Study type: Observational

The goal of the NEO2 BAV registry is to investigate the safety, effectiveness, and clinical performance of TAVI using the ACURATE neo2 valve in patients with severe BAV stenosis. The clinical, procedural, and imaging characteristics will be collected from patients with severe BAV stenosis, regardless of the phenotype, and treated with TAVI using the ACURATE neo2 bioprosthesis worldwide.